DITPA - Zarion Pharmaceuticals

Drug Profile

DITPA - Zarion Pharmaceuticals

Alternative Names: 3,5-diiodothyropropionic acid - Zarion Pharmaceuticals

Latest Information Update: 15 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zarion Pharmaceuticals
  • Class Cardiotonics; Diiodothyronines; Propionic acids; Small molecules
  • Mechanism of Action Thyroid hormone modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Allan-Herndon-Dudley syndrome
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Allan-Herndon-Dudley syndrome

Most Recent Events

  • 03 Mar 2014 Phase-II clinical trials in Allan-Herndon-Dudley syndrome in Australia (PO)
  • 14 May 2013 DITPA - Zarion Pharmaceuticals receives Orphan Drug status for Allan-Herndon-Dudley syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top